| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Veterans | 40 | 2025 | 751 | 7.920 |
Why?
|
| United States Department of Veterans Affairs | 23 | 2025 | 534 | 2.830 |
Why?
|
| Depression, Postpartum | 11 | 2024 | 132 | 2.770 |
Why?
|
| Pregnancy | 37 | 2024 | 2315 | 1.900 |
Why?
|
| Veterans Health | 12 | 2025 | 158 | 1.800 |
Why?
|
| Musculoskeletal Pain | 2 | 2024 | 28 | 1.710 |
Why?
|
| Prenatal Care | 6 | 2021 | 173 | 1.610 |
Why?
|
| Depression | 12 | 2023 | 883 | 1.590 |
Why?
|
| Military Personnel | 7 | 2024 | 105 | 1.550 |
Why?
|
| Mental Health Services | 5 | 2022 | 277 | 1.420 |
Why?
|
| Maternal Health Services | 7 | 2024 | 64 | 1.350 |
Why?
|
| Pregnancy Complications | 5 | 2024 | 378 | 1.230 |
Why?
|
| Cesarean Section | 3 | 2024 | 98 | 1.170 |
Why?
|
| Chronic Pain | 2 | 2024 | 150 | 1.170 |
Why?
|
| United States | 29 | 2025 | 7718 | 1.070 |
Why?
|
| Female | 64 | 2025 | 32478 | 1.050 |
Why?
|
| Postpartum Period | 6 | 2024 | 195 | 1.040 |
Why?
|
| Qualitative Research | 4 | 2024 | 670 | 1.030 |
Why?
|
| Stress Disorders, Post-Traumatic | 7 | 2024 | 397 | 0.970 |
Why?
|
| Depressive Disorder, Major | 3 | 2023 | 254 | 0.940 |
Why?
|
| Adult | 40 | 2025 | 16623 | 0.870 |
Why?
|
| Personal Autonomy | 1 | 2024 | 68 | 0.860 |
Why?
|
| Health Services Accessibility | 7 | 2024 | 552 | 0.860 |
Why?
|
| Mothers | 3 | 2024 | 275 | 0.800 |
Why?
|
| Infertility | 1 | 2023 | 31 | 0.800 |
Why?
|
| Evidence-Based Practice | 1 | 2023 | 83 | 0.790 |
Why?
|
| Racism | 1 | 2024 | 88 | 0.780 |
Why?
|
| Pain Management | 1 | 2024 | 163 | 0.780 |
Why?
|
| Humans | 71 | 2025 | 62653 | 0.780 |
Why?
|
| Peripartum Period | 4 | 2020 | 21 | 0.770 |
Why?
|
| Mental Health | 7 | 2023 | 363 | 0.710 |
Why?
|
| Delivery of Health Care, Integrated | 3 | 2019 | 120 | 0.710 |
Why?
|
| Perinatal Care | 4 | 2022 | 65 | 0.700 |
Why?
|
| Anxiety | 3 | 2023 | 421 | 0.700 |
Why?
|
| Burnout, Professional | 1 | 2022 | 133 | 0.680 |
Why?
|
| Hepatitis, Alcoholic | 4 | 2023 | 77 | 0.670 |
Why?
|
| Smoking Cessation | 2 | 2021 | 551 | 0.590 |
Why?
|
| Continuity of Patient Care | 2 | 2019 | 173 | 0.580 |
Why?
|
| Analgesics, Opioid | 3 | 2023 | 532 | 0.570 |
Why?
|
| Telemedicine | 1 | 2022 | 318 | 0.560 |
Why?
|
| Sex Offenses | 3 | 2024 | 46 | 0.550 |
Why?
|
| Oxytocics | 1 | 2017 | 14 | 0.530 |
Why?
|
| Pregnancy Outcome | 2 | 2015 | 193 | 0.530 |
Why?
|
| Cohort Studies | 9 | 2024 | 2537 | 0.530 |
Why?
|
| Oxytocin | 1 | 2017 | 45 | 0.520 |
Why?
|
| Infant, Newborn | 7 | 2023 | 1338 | 0.510 |
Why?
|
| Premenstrual Syndrome | 2 | 2017 | 99 | 0.510 |
Why?
|
| Prescription Drugs | 1 | 2015 | 51 | 0.470 |
Why?
|
| Anxiety Disorders | 1 | 2017 | 192 | 0.470 |
Why?
|
| Infant | 6 | 2023 | 1594 | 0.460 |
Why?
|
| Young Adult | 11 | 2020 | 4633 | 0.440 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2023 | 476 | 0.420 |
Why?
|
| Interviews as Topic | 2 | 2024 | 506 | 0.380 |
Why?
|
| Adolescent | 11 | 2019 | 6165 | 0.350 |
Why?
|
| Middle Aged | 18 | 2024 | 17358 | 0.330 |
Why?
|
| Exercise | 1 | 2017 | 937 | 0.320 |
Why?
|
| Women's Health | 2 | 2025 | 369 | 0.290 |
Why?
|
| Health Personnel | 2 | 2022 | 363 | 0.290 |
Why?
|
| Prevalence | 4 | 2021 | 1345 | 0.280 |
Why?
|
| gamma-Aminobutyric Acid | 2 | 2018 | 75 | 0.270 |
Why?
|
| Organ Transplantation | 2 | 2020 | 54 | 0.260 |
Why?
|
| Iraq War, 2003-2011 | 5 | 2019 | 58 | 0.260 |
Why?
|
| Cross-Sectional Studies | 8 | 2022 | 2540 | 0.260 |
Why?
|
| Surveys and Questionnaires | 7 | 2023 | 2646 | 0.250 |
Why?
|
| Male | 18 | 2025 | 29472 | 0.240 |
Why?
|
| Drug Prescriptions | 2 | 2017 | 168 | 0.230 |
Why?
|
| Child | 7 | 2024 | 4436 | 0.230 |
Why?
|
| Afghan Campaign 2001- | 4 | 2019 | 55 | 0.230 |
Why?
|
| Doulas | 1 | 2024 | 5 | 0.230 |
Why?
|
| Suicide, Attempted | 1 | 2025 | 106 | 0.220 |
Why?
|
| Sexual Harassment | 2 | 2023 | 15 | 0.220 |
Why?
|
| Interleukin-13 | 1 | 2023 | 37 | 0.210 |
Why?
|
| Women | 1 | 2024 | 44 | 0.210 |
Why?
|
| Health Services Research | 1 | 2025 | 270 | 0.210 |
Why?
|
| Stress, Psychological | 2 | 2019 | 469 | 0.210 |
Why?
|
| Public Policy | 1 | 2023 | 41 | 0.210 |
Why?
|
| Resilience, Psychological | 1 | 2024 | 60 | 0.210 |
Why?
|
| Perception | 1 | 2024 | 173 | 0.210 |
Why?
|
| Psychiatric Status Rating Scales | 3 | 2019 | 393 | 0.210 |
Why?
|
| Abortion, Spontaneous | 1 | 2023 | 31 | 0.210 |
Why?
|
| Age Factors | 3 | 2023 | 1554 | 0.200 |
Why?
|
| Community Health Services | 2 | 2021 | 127 | 0.200 |
Why?
|
| Pentoxifylline | 1 | 2022 | 8 | 0.200 |
Why?
|
| Mental Disorders | 3 | 2019 | 756 | 0.190 |
Why?
|
| Pneumonia, Staphylococcal | 1 | 2022 | 11 | 0.190 |
Why?
|
| Abortion, Induced | 1 | 2022 | 27 | 0.190 |
Why?
|
| Antidepressive Agents | 2 | 2022 | 225 | 0.190 |
Why?
|
| End Stage Liver Disease | 1 | 2022 | 33 | 0.190 |
Why?
|
| Serotonin and Noradrenaline Reuptake Inhibitors | 1 | 2022 | 11 | 0.190 |
Why?
|
| Job Satisfaction | 1 | 2022 | 136 | 0.190 |
Why?
|
| Breast Feeding | 1 | 2024 | 148 | 0.190 |
Why?
|
| Premature Birth | 1 | 2023 | 113 | 0.180 |
Why?
|
| Soft Tissue Infections | 1 | 2022 | 49 | 0.180 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2021 | 11 | 0.180 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2022 | 65 | 0.180 |
Why?
|
| Patient Selection | 1 | 2024 | 482 | 0.180 |
Why?
|
| Community-Acquired Infections | 1 | 2022 | 94 | 0.180 |
Why?
|
| Community Networks | 1 | 2021 | 31 | 0.180 |
Why?
|
| Bacteremia | 1 | 2022 | 94 | 0.180 |
Why?
|
| Vaccines | 1 | 2022 | 95 | 0.180 |
Why?
|
| Staphylococcal Infections | 1 | 2022 | 129 | 0.170 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 452 | 0.170 |
Why?
|
| Intimate Partner Violence | 1 | 2021 | 25 | 0.170 |
Why?
|
| Pandemics | 2 | 2022 | 663 | 0.170 |
Why?
|
| Prospective Studies | 7 | 2022 | 3258 | 0.170 |
Why?
|
| Decision Making | 1 | 2024 | 402 | 0.170 |
Why?
|
| Longitudinal Studies | 6 | 2021 | 1247 | 0.170 |
Why?
|
| Hepatitis B virus | 1 | 2020 | 15 | 0.170 |
Why?
|
| Sarcopenia | 1 | 2020 | 22 | 0.170 |
Why?
|
| Multiple Organ Failure | 1 | 2020 | 43 | 0.170 |
Why?
|
| HIV | 1 | 2020 | 70 | 0.160 |
Why?
|
| Reproductive Health Services | 1 | 2019 | 13 | 0.160 |
Why?
|
| Counseling | 1 | 2022 | 360 | 0.160 |
Why?
|
| Health Status | 2 | 2019 | 433 | 0.160 |
Why?
|
| Risk Factors | 9 | 2022 | 5302 | 0.160 |
Why?
|
| Health Policy | 1 | 2021 | 187 | 0.160 |
Why?
|
| Tissue Donors | 1 | 2020 | 153 | 0.160 |
Why?
|
| Acute-Phase Proteins | 1 | 2019 | 34 | 0.160 |
Why?
|
| Health Services | 1 | 2019 | 82 | 0.160 |
Why?
|
| Smoking | 2 | 2021 | 864 | 0.160 |
Why?
|
| Creatine | 1 | 2018 | 24 | 0.150 |
Why?
|
| Sexual Partners | 1 | 2019 | 75 | 0.150 |
Why?
|
| Macrophage Activation | 1 | 2019 | 119 | 0.150 |
Why?
|
| Hepacivirus | 1 | 2020 | 141 | 0.150 |
Why?
|
| Gyrus Cinguli | 1 | 2018 | 57 | 0.150 |
Why?
|
| Connectome | 1 | 2018 | 33 | 0.150 |
Why?
|
| Alcoholism | 1 | 2021 | 319 | 0.140 |
Why?
|
| Antigens, CD | 1 | 2019 | 348 | 0.140 |
Why?
|
| Sperm Count | 1 | 2017 | 15 | 0.140 |
Why?
|
| Recreation | 1 | 2017 | 21 | 0.130 |
Why?
|
| Cerebral Cortex | 1 | 2018 | 256 | 0.130 |
Why?
|
| Semen | 1 | 2017 | 44 | 0.130 |
Why?
|
| Disease Progression | 2 | 2019 | 1159 | 0.130 |
Why?
|
| Cigarette Smoking | 1 | 2017 | 57 | 0.130 |
Why?
|
| Prognosis | 3 | 2019 | 1724 | 0.130 |
Why?
|
| Steroids | 1 | 2016 | 54 | 0.130 |
Why?
|
| Sleep | 2 | 2020 | 225 | 0.130 |
Why?
|
| Referral and Consultation | 1 | 2019 | 421 | 0.130 |
Why?
|
| Ambulatory Care | 1 | 2018 | 310 | 0.130 |
Why?
|
| Membrane Glycoproteins | 1 | 2019 | 669 | 0.120 |
Why?
|
| Medical Record Linkage | 1 | 2015 | 21 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2014 | 445 | 0.120 |
Why?
|
| Mass Screening | 3 | 2020 | 686 | 0.120 |
Why?
|
| Length of Stay | 2 | 2020 | 804 | 0.120 |
Why?
|
| Body Mass Index | 2 | 2017 | 864 | 0.120 |
Why?
|
| Treatment Outcome | 5 | 2020 | 5587 | 0.120 |
Why?
|
| Quality of Life | 1 | 2022 | 1221 | 0.120 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 583 | 0.120 |
Why?
|
| Rehabilitation Centers | 1 | 2015 | 14 | 0.120 |
Why?
|
| Infertility, Female | 1 | 2015 | 46 | 0.120 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2014 | 4 | 0.120 |
Why?
|
| Case-Control Studies | 4 | 2022 | 1108 | 0.120 |
Why?
|
| Logistic Models | 2 | 2015 | 1273 | 0.120 |
Why?
|
| Retrospective Studies | 8 | 2022 | 6528 | 0.120 |
Why?
|
| Odds Ratio | 1 | 2017 | 768 | 0.110 |
Why?
|
| Pregnanolone | 3 | 2020 | 13 | 0.110 |
Why?
|
| Tracheostomy | 1 | 2015 | 36 | 0.110 |
Why?
|
| Carrier Proteins | 1 | 2019 | 705 | 0.110 |
Why?
|
| Hydrocortisone | 1 | 2016 | 192 | 0.110 |
Why?
|
| Cardiovascular Diseases | 1 | 2022 | 832 | 0.110 |
Why?
|
| Skilled Nursing Facilities | 1 | 2015 | 83 | 0.110 |
Why?
|
| Longevity | 1 | 2015 | 113 | 0.110 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2014 | 68 | 0.110 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2013 | 11 | 0.110 |
Why?
|
| Sertraline | 1 | 2013 | 58 | 0.110 |
Why?
|
| Weight Gain | 1 | 2014 | 170 | 0.100 |
Why?
|
| Fetus | 1 | 2013 | 99 | 0.100 |
Why?
|
| Primary Health Care | 1 | 2019 | 681 | 0.100 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2013 | 39 | 0.100 |
Why?
|
| Benzodiazepines | 1 | 2013 | 100 | 0.100 |
Why?
|
| Lymphoma | 1 | 2013 | 101 | 0.100 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2012 | 25 | 0.100 |
Why?
|
| Central Nervous System Diseases | 1 | 2013 | 57 | 0.100 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2012 | 51 | 0.100 |
Why?
|
| Colonoscopy | 1 | 2013 | 97 | 0.100 |
Why?
|
| Perimenopause | 1 | 2012 | 31 | 0.100 |
Why?
|
| Wounds and Injuries | 1 | 2015 | 238 | 0.100 |
Why?
|
| Weight Loss | 1 | 2014 | 272 | 0.100 |
Why?
|
| Body Weight | 1 | 2013 | 377 | 0.090 |
Why?
|
| Parturition | 2 | 2023 | 55 | 0.090 |
Why?
|
| Severity of Illness Index | 3 | 2022 | 1540 | 0.090 |
Why?
|
| Quality Improvement | 1 | 2015 | 433 | 0.090 |
Why?
|
| Neoplastic Stem Cells | 1 | 2012 | 202 | 0.090 |
Why?
|
| Neoplasm Proteins | 1 | 2012 | 283 | 0.090 |
Why?
|
| Postmenopause | 1 | 2012 | 236 | 0.090 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2012 | 189 | 0.080 |
Why?
|
| Aged | 9 | 2019 | 14249 | 0.080 |
Why?
|
| Colorectal Neoplasms | 1 | 2013 | 280 | 0.080 |
Why?
|
| Bipolar Disorder | 1 | 2012 | 246 | 0.080 |
Why?
|
| Early Detection of Cancer | 1 | 2013 | 314 | 0.080 |
Why?
|
| Neoplasms | 1 | 2019 | 1350 | 0.080 |
Why?
|
| Disease-Free Survival | 3 | 2014 | 241 | 0.080 |
Why?
|
| 20-alpha-Dihydroprogesterone | 2 | 2020 | 7 | 0.080 |
Why?
|
| Desoxycorticosterone | 2 | 2020 | 7 | 0.080 |
Why?
|
| Progesterone | 2 | 2020 | 162 | 0.070 |
Why?
|
| Aged, 80 and over | 5 | 2015 | 5403 | 0.070 |
Why?
|
| Aging | 1 | 2012 | 740 | 0.060 |
Why?
|
| Biomarkers | 2 | 2023 | 1382 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2019 | 416 | 0.060 |
Why?
|
| Psychotherapy, Group | 1 | 2025 | 34 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 2019 | 933 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 1 | 2025 | 137 | 0.060 |
Why?
|
| Depressive Disorder | 2 | 2020 | 285 | 0.060 |
Why?
|
| Lipocalin-2 | 1 | 2023 | 9 | 0.050 |
Why?
|
| alpha-Fetoproteins | 1 | 2023 | 15 | 0.050 |
Why?
|
| Rape | 1 | 2023 | 15 | 0.050 |
Why?
|
| Gender Identity | 1 | 2024 | 67 | 0.050 |
Why?
|
| Stillbirth | 1 | 2023 | 18 | 0.050 |
Why?
|
| Employment | 1 | 2024 | 127 | 0.050 |
Why?
|
| Birth Weight | 1 | 2023 | 85 | 0.050 |
Why?
|
| Fertilization | 1 | 2023 | 79 | 0.050 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2022 | 27 | 0.050 |
Why?
|
| Fertilization in Vitro | 1 | 2023 | 84 | 0.050 |
Why?
|
| Methylprednisolone | 1 | 2022 | 34 | 0.050 |
Why?
|
| Leukocidins | 1 | 2022 | 8 | 0.050 |
Why?
|
| Exotoxins | 1 | 2022 | 9 | 0.050 |
Why?
|
| Neoplasm Staging | 2 | 2014 | 486 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2023 | 319 | 0.050 |
Why?
|
| Lactation | 1 | 2022 | 69 | 0.050 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2022 | 66 | 0.050 |
Why?
|
| Fever | 1 | 2022 | 66 | 0.050 |
Why?
|
| Public Health | 1 | 2023 | 186 | 0.050 |
Why?
|
| Bacterial Toxins | 1 | 2022 | 60 | 0.050 |
Why?
|
| Norepinephrine | 1 | 2022 | 103 | 0.050 |
Why?
|
| Zinc | 1 | 2022 | 92 | 0.050 |
Why?
|
| Sex Factors | 2 | 2015 | 972 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2025 | 729 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2025 | 428 | 0.040 |
Why?
|
| Object Attachment | 1 | 2020 | 19 | 0.040 |
Why?
|
| Staphylococcus aureus | 1 | 2022 | 177 | 0.040 |
Why?
|
| Pregnenolone | 1 | 2020 | 4 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2022 | 173 | 0.040 |
Why?
|
| Prazosin | 1 | 2020 | 9 | 0.040 |
Why?
|
| Mother-Child Relations | 1 | 2020 | 46 | 0.040 |
Why?
|
| Tobacco Smoking | 1 | 2020 | 20 | 0.040 |
Why?
|
| Pathology, Molecular | 1 | 2020 | 11 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2021 | 284 | 0.040 |
Why?
|
| Chromatography, Liquid | 1 | 2020 | 131 | 0.040 |
Why?
|
| Serologic Tests | 1 | 2020 | 37 | 0.040 |
Why?
|
| Hepatitis B | 1 | 2020 | 32 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2021 | 196 | 0.040 |
Why?
|
| New Jersey | 1 | 2019 | 26 | 0.040 |
Why?
|
| Demography | 1 | 2020 | 172 | 0.040 |
Why?
|
| Vaccination | 1 | 2022 | 352 | 0.040 |
Why?
|
| Texas | 1 | 2019 | 57 | 0.040 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2020 | 146 | 0.040 |
Why?
|
| Patient Outcome Assessment | 1 | 2019 | 53 | 0.040 |
Why?
|
| Liver Function Tests | 1 | 2019 | 39 | 0.040 |
Why?
|
| Puerto Rico | 1 | 2019 | 132 | 0.040 |
Why?
|
| Communicable Diseases | 1 | 2019 | 88 | 0.040 |
Why?
|
| Proton Magnetic Resonance Spectroscopy | 1 | 2018 | 12 | 0.040 |
Why?
|
| ROC Curve | 1 | 2019 | 277 | 0.040 |
Why?
|
| Suicidal Ideation | 1 | 2019 | 116 | 0.040 |
Why?
|
| Cause of Death | 1 | 2019 | 221 | 0.040 |
Why?
|
| Hepatitis C | 1 | 2020 | 151 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2019 | 453 | 0.040 |
Why?
|
| Social Support | 1 | 2020 | 370 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2019 | 576 | 0.040 |
Why?
|
| Parents | 1 | 2021 | 381 | 0.030 |
Why?
|
| Self Efficacy | 1 | 2018 | 202 | 0.030 |
Why?
|
| Marital Status | 1 | 2017 | 45 | 0.030 |
Why?
|
| Semen Analysis | 1 | 2017 | 20 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 726 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2019 | 316 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2019 | 748 | 0.030 |
Why?
|
| Receptors, GABA-A | 1 | 2016 | 25 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 1077 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 409 | 0.030 |
Why?
|
| Saliva | 1 | 2016 | 103 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 431 | 0.030 |
Why?
|
| Vincristine | 1 | 2014 | 27 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2014 | 79 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2018 | 517 | 0.030 |
Why?
|
| Prednisone | 1 | 2014 | 86 | 0.030 |
Why?
|
| Pain | 1 | 2017 | 406 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2014 | 99 | 0.030 |
Why?
|
| Trauma Centers | 1 | 2015 | 118 | 0.030 |
Why?
|
| Hallucinations | 1 | 2013 | 16 | 0.030 |
Why?
|
| Metabolism | 1 | 2013 | 13 | 0.030 |
Why?
|
| Massachusetts | 1 | 2019 | 2061 | 0.030 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2013 | 120 | 0.030 |
Why?
|
| Sigmoidoscopy | 1 | 2013 | 17 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2013 | 118 | 0.030 |
Why?
|
| Family | 1 | 2015 | 240 | 0.030 |
Why?
|
| Tandem Repeat Sequences | 1 | 2012 | 26 | 0.030 |
Why?
|
| Gene Duplication | 1 | 2012 | 31 | 0.030 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2012 | 25 | 0.030 |
Why?
|
| Cytarabine | 1 | 2012 | 35 | 0.030 |
Why?
|
| HIV Infections | 1 | 2020 | 962 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 1586 | 0.020 |
Why?
|
| Overweight | 1 | 2014 | 249 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2012 | 198 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2013 | 463 | 0.020 |
Why?
|
| Premenopause | 1 | 2012 | 59 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2019 | 2039 | 0.020 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2012 | 80 | 0.020 |
Why?
|
| Global Health | 1 | 2013 | 182 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 370 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2013 | 738 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2015 | 405 | 0.020 |
Why?
|
| Affect | 1 | 2012 | 125 | 0.020 |
Why?
|
| Critical Care | 1 | 2015 | 389 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 775 | 0.020 |
Why?
|
| Patient Discharge | 1 | 2015 | 505 | 0.020 |
Why?
|
| Survival Rate | 1 | 2013 | 839 | 0.020 |
Why?
|
| Antipsychotic Agents | 1 | 2013 | 302 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2013 | 1139 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2012 | 348 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 2149 | 0.020 |
Why?
|
| Incidence | 1 | 2013 | 1367 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 2445 | 0.020 |
Why?
|
| Hospitalization | 1 | 2015 | 1344 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2013 | 1284 | 0.020 |
Why?
|
| Mutation | 1 | 2012 | 2573 | 0.010 |
Why?
|